Home » Newsletters » BioWorld Science

BioWorld Science

March 17, 2003

View Archived Issues

Radiolabeled neuropeptide Y5 receptor antagonists for brain imaging

Novel viral polymerase inhibitors identified at Boehringer Ingelheim

New antiinflammatory IKK-2 inhibitors in early development at AstraZeneca

Significant milestones reached in 2002 at NeuroSearch

New data on the pharmacokinetics and safety of ciclesonide

Pain relief induced by intravenous amantadine in diabetic peripheral neuropathy

Bryostatin-1 increases survival in advanced renal cell carcinoma

Bayer claims novel glucose- and triglyceride-lowering agents for diabetes and other uses

Novel HDAC inhibitors in Roche development pipeline

New antibacterial oxazolidinones in early development at Cipla

Aventis scientists design new imidazolidine-based VLA-4 antagonists

Inex: 2002 results, 2003 milestones

Yuhan granted marketing rights to prulifloxacin in Korea

ML-04 shows efficacy in chronic prostatitis

Low-dose Prempro approved by FDA

NCI grant for trial of NCX-4016 in prevention of colon cancer

Maxim receives NCI SBIR grant for MX-2167

DP-109 reduces beta-amyloid plaque deposition in models of Alzheimer's disease

Phase II DX-88 study in angioedema completes patient treatment

BAL-5788 receives fast track designation for cSSSI

ARISE phase III protocol adequate to support AGI-1067 NDA

Licensing activity update for Zindaclin

FDA approves first fusion inhibitor for HIV infection

Fesoterodine pharmacodynamics and pharmacokinetics after multiple oral doses in man

GSK celebrates the international launch of Avodart

Bladder selectivity demonstrated in preclinical and clinical studies with YM-905

Results from European phase III trial of Plenaxis discussed at EAU meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...